Matches in Nanopublications for { ?s ?p "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP710370.RAtIOiLWirolnNE4Nw07J6jtKsnB-ifLE4emZ7fGDdhjM130_assertion description "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP710370.RAtIOiLWirolnNE4Nw07J6jtKsnB-ifLE4emZ7fGDdhjM130_provenance.
- NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_assertion description "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP583774.RAezwQz_g5j5J97-LTMWlqFfIqe0W1sG5VgZ4R9kP2eJU130_provenance.
- NP583815.RAeK8mjjiB4binhSyLBqyfJCd1JCsRgxCbHmLucBmv-yA130_assertion description "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP583815.RAeK8mjjiB4binhSyLBqyfJCd1JCsRgxCbHmLucBmv-yA130_provenance.
- NP535310.RAMYM9mhXcAOnNmTzbVNuCw4Za0FqULec5nCEseUrC7wg130_assertion description "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP535310.RAMYM9mhXcAOnNmTzbVNuCw4Za0FqULec5nCEseUrC7wg130_provenance.
- assertion description "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP324119.RAa0-wWPgvLMNGVlNR9O-euEktDQVqylc69UiXrFFXdrA130_assertion description "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP324119.RAa0-wWPgvLMNGVlNR9O-euEktDQVqylc69UiXrFFXdrA130_provenance.
- NP324121.RAxtBhov2sVjaRHptl9VHS_if9-52y7yA0knQPSfHzRwY130_assertion description "[Amplification of the CBFbeta/MYH11 fusion transcript by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) and assess the risk for disease relapse in inv(16)(p13q22) acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP324121.RAxtBhov2sVjaRHptl9VHS_if9-52y7yA0knQPSfHzRwY130_provenance.